Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,575 stopped studies mapped to Malignant Breast Neoplasm and descendants · 90% state a reason
Over the 1,575 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04190433 | Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline… | Phase 2 | withdrawn | Dec 9, 2019 | Mayo Clinic | Administratively closed due to low/no accrual | Enrollment / accrual |
| NCT04942054 | A Study in Patients With Advanced Breast Cancer | Phase 1 | terminated | Jun 28, 2021 | Sun Pharma Advanced Research Company Limited | The decision to close is due commercial reasons only | Other (stated, no rule matched) |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | Phase 1 | withdrawn | Mar 20, 2023 | Dana-Farber Cancer Institute | On hold | Other (stated, no rule matched) |
| NCT00597597 | Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative… | Phase 2 | terminated | Jan 18, 2008 | Rush University Medical Center | not enough patients enrolled | Enrollment / accrual |
| NCT04088435 | Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer | — | terminated | Sep 12, 2019 | University of Louisville | Low accrual | Enrollment / accrual |
| NCT04535492 | Technology-Based Cancer Screening Intervention | N/A | withdrawn | Sep 2, 2020 | Medical University of South Carolina | No further funding | Funding |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus… | Phase 3 | terminated | Apr 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Sponsor R \& D Strategy Adjustment | Sponsor / business decision |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian… | Early Phase 1 | withdrawn | May 10, 2022 | OHSU Knight Cancer Institute | PI discretion | Other (stated, no rule matched) |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast… | Phase 1 | withdrawn | May 4, 2021 | Memorial Sloan Kettering Cancer Center | The sponsor closed the study due to discontinuing their onapristone program | Other (stated, no rule matched) |
| NCT01147016 | Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III… | Phase 2 | terminated | Jun 22, 2010 | Barbara Ann Karmanos Cancer Institute | Primary co-investigator leaving the institution \& funding transfer. | Investigator |
| NCT04396626 | HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes | — | terminated | May 20, 2020 | Pfizer | The study was prematurely discontinued due to significant data quality issues on August 26, 2021.… | Safety / toxicity |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel… | Phase 3 | suspended | Dec 23, 2016 | SynCore Biotechnology Co., Ltd. | study design reconsideration | Other (stated, no rule matched) |
| NCT04350957 | Low-dose Imaging Technique (LITE) | N/A | withdrawn | Apr 17, 2020 | University of Chicago | PI left institution due to family emergency prior to IRB approval. | Investigator |
| NCT03574194 | Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy | N/A | terminated | Jun 29, 2018 | West Virginia University | Suspended due to COVID-19 pandemic | COVID-19 / pandemic |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT03919214 | Hypertension Management in Cancer Patients | N/A | terminated | Apr 18, 2019 | Duke University | Initially suspended due to Covid-19. After much consideration, it was determined that we do not… | COVID-19 / pandemic |
| NCT04189263 | BREADS: Breast Adjuvant Diet Study | Phase 2 | terminated | Dec 6, 2019 | Farin Amersi | Low participant compliance, slow recruitment | Enrollment / accrual |
| NCT05338281 | NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT(NPWTinDIEP) | N/A | withdrawn | Apr 21, 2022 | Western University, Canada | Study details changed, new Trial Registration process begun for modified protocol | Other (stated, no rule matched) |
| NCT00004935 | Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That… | Phase 3 | terminated | Jan 27, 2003 | Swiss Cancer Institute | Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely. | Other (stated, no rule matched) |
| NCT02322814 | A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or… | Phase 2 | terminated | Dec 23, 2014 | Hoffmann-La Roche | Sponsor's decision | Sponsor / business decision |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative… | Phase 2 | terminated | Jul 28, 2020 | EMD Serono Research & Development Institute, Inc. | The study was prematurely discontinued by the sponsor due to probability of success which was too… | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03630601 | Photoacoustic Imaging in Diagnosing Changes in Tumors in Participants With Breast Cancer,… | N/A | terminated | Aug 15, 2018 | Roswell Park Cancer Institute | Diagnostic issues | Other (stated, no rule matched) |
| NCT03121989 | Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients…(LABC) | Phase 1 | withdrawn | Apr 20, 2017 | Sunnybrook Health Sciences Centre | Funding completed | Funding |
| NCT00323063 | Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer | Phase 2 | terminated | May 9, 2006 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT05079360 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of… | Phase 2 | withdrawn | Oct 15, 2021 | Veru Inc. | Decided to halt and will potentially reopen in the future. | Other (stated, no rule matched) |
| NCT04252768 | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New…(AIPAC-002) | Phase 1 | withdrawn | Feb 5, 2020 | Immutep S.A.S. | Replaced by other study NCT05747794 | Other (stated, no rule matched) |
| NCT04826016 | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative…(POLTER) | Phase 1 / Phase 2 | withdrawn | Apr 1, 2021 | MedSIR | Funder decision | Other (stated, no rule matched) |
| NCT03354611 | Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging | Phase 2 / Phase 3 | terminated | Nov 28, 2017 | Koning Corporation | The study progress doesn't meet the sponsor's requirement | Other (stated, no rule matched) |
| NCT00543127 | Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole | Phase 3 | terminated | Oct 12, 2007 | Spanish Breast Cancer Research Group | Unjustified decision of company that funded the trial. | Funding |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With…(REVEAL) | Phase 1 / Phase 2 | terminated | Feb 19, 2018 | Nektar Therapeutics | Based on the overall results from the Phase 1 part of the study the sponsor decided to end the… | Safety / toxicity |
| NCT05228210 | Breast Cancer Self-Efficacy Scale for Partners(BCSES-P) | — | terminated | Feb 8, 2022 | Indiana University | PI no longer working at Indiana University; | Other (stated, no rule matched) |
| NCT01792882 | Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples(GBCPRT0008) | — | withdrawn | Feb 15, 2013 | Global BioClinical | not stated | Not stated |
| NCT03137693 | Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer | N/A | terminated | May 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | no responders/lack of efficacy | Efficacy / futility |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | — | suspended | Aug 18, 2022 | Guangzhou Women and Children's Medical Center | Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily. | COVID-19 / pandemic |
| NCT03367689 | A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With…(NOBROLA) | Phase 2 | terminated | Dec 11, 2017 | MedSIR | Very slow recruitment due to subject profile | Enrollment / accrual |
| NCT03510988 | Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed… | N/A | terminated | Apr 27, 2018 | Weill Medical College of Cornell University | Temporarily paused per study team for interim data review. | Other (stated, no rule matched) |
| NCT03931551 | Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced…(OPHELIA) | Phase 2 | terminated | Apr 30, 2019 | MedSIR | Very slow recruitment due to subject profile | Enrollment / accrual |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid… | Phase 1 | terminated | Jul 15, 2016 | Calithera Biosciences, Inc | Insufficient efficacy of drug; no safety concern | Safety / toxicity |
| NCT02067416 | PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer | Phase 2 | withdrawn | Feb 20, 2014 | Jenny C. Chang, MD | Funding agent withdrew funding | Funding |
| NCT05533320 | Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in… | N/A | withdrawn | Sep 9, 2022 | City of Hope Medical Center | PI decided to withdraw | Other (stated, no rule matched) |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT02658812 | Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be… | Phase 2 | terminated | Jan 20, 2016 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies -… | Phase 1 / Phase 2 | terminated | Mar 19, 2015 | Incyte Corporation | not stated | Not stated |
| NCT03666819 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone… | Phase 2 | withdrawn | Sep 12, 2018 | Mayo Clinic | Manufacturer will not be supporting this study | Drug supply |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple… | Early Phase 1 | withdrawn | Jan 30, 2020 | Mayo Clinic | study was dropped | Other (stated, no rule matched) |
| NCT03636776 | Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast…(EPOCA) | N/A | terminated | Aug 17, 2018 | Institut Cancerologie de l'Ouest | The sponsor has set up a secondary competitive study concerning the same population and whose… | Other (stated, no rule matched) |
| NCT01022138 | Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With… | Phase 2 | terminated | Dec 1, 2009 | Barbara Ann Karmanos Cancer Institute | not stated | Not stated |
| NCT04316169 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive… | Phase 1 | withdrawn | Mar 20, 2020 | Medical College of Wisconsin | Funding and PI leaving institution | Funding |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | N/A | withdrawn | Jun 28, 2021 | Institut du Cancer de Montpellier - Val d'Aurelle | please refer to NCT05621837 | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated May 24, 2023source: clinicaltrials